Amplitude Vascular Systems vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Intravascular Lithotripsy & Calcified Artery Treatment Devices
Amplitude Vascular Systems (AVS) is a medical device company developing the Pulse IVL system — a high-frequency pulsatile pressure wave device for treating calcified peripheral artery disease; raised $75M+ total;
About
Amplitude Vascular Systems (AVS) is a medical device company headquartered in Fremont, California, founded to develop next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral artery disease (PAD). The company''s flagship product, the Pulse IVL system, delivers high-frequency pulsatile pressure waves through a catheter-based device to fracture calcium deposits in arterial walls — restoring vessel compliance and improving blood flow in patients with calcified, obstructed arteries in the legs, below-the-knee vessels, and other peripheral vascular territories. Calcified PAD is a significant and growing clinical problem, particularly in diabetic patients and the aging population, where conventional balloon angioplasty and stenting are less effective due to hard, calcified lesion morphology.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Amplitude Vascular Systems vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.